SynthesisJournal of cachexia, sarcopenia and muscle2022
A systematic review examining the relationship between cytokines and cachexia in incurable cancer.
Synthesis in Journal of cachexia, sarcopenia and muscle, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 4 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Prevalence of sarcopenia in esophageal cancer patients receiving preoperative neoadjuvant therapy: a systematic review and meta-analysis.International journal of clinical oncology · 2026Pooled it
- Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series.Journal of cachexia, sarcopenia and muscle · 2024Pooled it
- A systematic review and Bayesian meta-analysis assessing intelectin-1 in cancer patients and healthy individuals.Frontiers in oncology · 2024Pooled it
- A systematic review examining the relationship between cytokines and cachexia in incurable cancer.Journal of cachexia, sarcopenia and muscle · 2022Pooled it
- Trial
- Neuroendocrine regulation of appetite and energy balance in metabolic disorders.IBRO neuroscience reports · 2026Review
- Phloretin Attenuates Cancer Cachexia-Induced Skeletal Muscle Wasting Associated with the Modulation of STAT3 Signaling.Biomedicines · 2026Article
- Total flavonoids extracted fromTranslational cancer research · 2026Article
- Sex impacts inflammatory signaling, body composition, and physical function in tumor-bearing mice receiving chemotherapy.American journal of physiology. Cell physiology · 2026Article
- Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma.Communications medicine · 2025Article
- Sarcopenia and Cachexia in Older Patients with Cancer: Pathophysiology, Diagnosis, Impact on Outcomes, and Management Strategies.Drugs & aging · 2025Review
- New Horizons with Growth Differentiation Factor 15 in Oncology: From Cancer Cachexia and Tumour Immunity to Novel Therapeutic Strategies.Current oncology (Toronto, Ont.) · 2025Review
- Role of Cytokines and Inflammation in the Development of Cachexia in Cancer Patients.Indian journal of surgical oncology · 2025Review
- Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.Cancer discovery · 2025Review
- Early molecular changes predict cancer cachexia in LKB1-deleted mouse models of NSCLC.Clinical and translational medicine · 2025Article
- Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis.Investigational new drugs · 2025Article
- Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma.Journal for immunotherapy of cancer · 2025Article
- Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers.ESMO open · 2025Article
- Immune mediation between sarcopenia, performance status, and survival in gastric cancer patients undergoing radical resection.Frontiers in oncology · 2025Article
- Unraveling the role of STAT3 in Cancer Cachexia: pathogenic mechanisms and therapeutic opportunities.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Cancer cachexia is an unmet clinical need that affects more than 50% of patients with cancer. The systemic inflammatory response, which is mediated by a network of cytokines, has an established role in the genesis and maintenance of cancer as well as in cachexia; yet, the specific role of the cytokine milieu in cachexia requires elucidation. This systematic review aims to examine the relationship between cytokines and the cachexia syndrome in patients with incurable cancer. The databases MEDLINE, EMBASE, CINAHL, CENTRAL, PsycINFO, and Web of Science were searched for studies published between 01/01/2004 and 06/01/2020. Included studies measured cytokines and their relationship with cachexia and related symptoms/signs in adults with incurable cancer. After title screening (n = 5202), the abstracts (n = 1264) and the full-text studies (n = 322) were reviewed independently by two authors. The quality assessment of the selected papers was conducted using the modified Downs and Black checklist. Overall, 1277 patients with incurable cancer and 155 healthy controls were analysed in the 17 eligible studies. The mean age of the patients was 64 ± 15 (mean ± standard deviation). Only 34% of included participants were female. The included studies were assessed as moderate-quality to high-quality evidence (mean quality score: 7.8; range: 5-10). A total of 31 cytokines were examined in this review, of which interleukin-6 (IL-6, 14 studies) and tumour necrosis factor-α (TNF-α, 12 studies) were the most common. The definitions of cachexia and the weight-loss thresholds were highly variable across studies. Although the data could not be meta-analysed due to the high degree of methodological heterogeneity, the findings were discussed in a systematic manner. IL-6, TNF-α, and IL-8 were greater in cachectic patients compared with healthy individuals. Also, IL-6 levels were higher in cachectic participants as opposed to non-cachectic patients. Leptin, interferon-γ, IL-1β, IL-10, adiponectin, and ghrelin did not demonstrate any significant difference between groups when individuals with cancer cachexia were compared against non-cachectic patients or healthy participants. These findings suggest that a network of cytokines, commonly IL-6, TNF-α, and IL-8, are associated with the development of cachexia. Yet, this relationship is not proven to be causative and future studies should opt for longitudinal designs with consistent methodological approaches, as well as adequate techniques for analysing and reporting the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.